系统构建和外部验证鼻咽癌免疫相关预后模型。
Systematic construction and external validation of an immune-related prognostic model for nasopharyngeal carcinoma.
机构信息
Department of Clinical Nutrition, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, Guangdong, China.
出版信息
Head Neck. 2022 May;44(5):1086-1098. doi: 10.1002/hed.26996. Epub 2022 Feb 15.
BACKGROUND
We attempted to identify the most reliable immune-related index for predicting nasopharyngeal carcinoma (NPC) prognosis and to reveal its precise and integrated relationship with NPC progression.
METHOD
One thousand seven hundred and six patients with newly diagnosed NPC (1320 from the primary cohort and 386 from the validated cohort) from January 2010 to March 2014 were enrolled. Clinical features and 12 immune-related variables were analyzed.
RESULTS
A high absolute lymphocyte count (ALC; >3.2 × 10 /L) correlated with a poor prognosis of patients with NPC. Significant OS differences were discovered between patients with high ALC and no ALC elevation (p < 0.05, in primary cohort), showing similar prognostic risk to patients with advanced NPC (p > 0.05, in validated cohort). ALC improved the predictive performance of the basic tumor-node-metastasis prognostic model (p = 0.025), which was reliably validated in the external independent cohort.
CONCLUSION
High ALC is a surrogate marker for improved prognostic risk stratification in NPC.
背景
我们试图确定最可靠的免疫相关指标来预测鼻咽癌（NPC）的预后，并揭示其与 NPC 进展的确切和综合关系。
方法
我们纳入了 1706 名 2010 年 1 月至 2014 年 3 月期间新诊断为 NPC 的患者（原发性队列 1320 例，验证性队列 386 例）。分析了临床特征和 12 个免疫相关变量。
结果
高绝对淋巴细胞计数（ALC；>3.2×10 /L）与 NPC 患者的不良预后相关。高 ALC 组和无 ALC 升高组的患者的 OS 差异具有统计学意义（p<0.05，在原发性队列中），与晚期 NPC 患者的预后风险相似（p>0.05，在验证性队列中）。ALC 改善了基本肿瘤-淋巴结-转移预后模型的预测性能（p=0.025），在外部独立队列中得到了可靠验证。
结论
高 ALC 是 NPC 中改善预后风险分层的替代标志物。
Zotero 插件